<img src="https://ml.globenewswire.com/Resource/Download/a1e3887d-3378-46c5-938d-2b0d5a7c825f?size=2" nborder="0" align="left" hspace="5" vspace="5" title="NeurAxis Logo.png" alt="NeurAxis, Inc."/>CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 11, 2026, at 9:00am ET Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060 Webcast: <a href="https://www.globenewswire.com/Tracker?data=MTOVWlVYRgU3xeWG4c5V0jOgv8_y-6IHX98rdSPbxUk1Sab-ysn0jtF7_SNyhVI08OLq7Wa51jzHLo4YanhlUr6ls-m9_1-_9mQojbW7P-Bw7jZuyiqD7_q7KR0yFLXrJ98ZWm1t0c7li7KxYP1rCw==" rel="nofollow" target="_blank" title="">https://app.webinar.net/E5zrP9X7wLY</a> Replay: Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088 Replay access code: 8443629 Webcast: <a href="https://www.globenewswire.com/Tracker?data=MTOVWlVYRgU3xeWG4c5V0jOgv8_y-6IHX98rdSPbxUnqsNiAQ8zI-yVda-Xn5Ammwe8WLfVJCakN5TyDicTbSQ4EK86X2R2FyPKu5oq6Mb_8ksQ2pskcruiXJ5EPKpgyFoysGa0Q28mQNI5lfZYZPQ==" rel="nofollow" target="_blank" title="">https://app.webinar.net/E5zrP9X7wLY</a> About NeurAxis, Inc. NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=y4AFcyLu7HDDtGKZGJbf-s81ArxmyZ6KMIIYFO13wV8QopHCDk09ntPcQkGcFD7Tn7w3HZS-9YuSpwVBRUgANHQmyd-cpM1oGSyoSmDIDIg=" rel="nofollow" target="_blank" title="">http://neuraxis.com</a>. Investor Relations Lytham Partners Ben Shamsian 646-829-9701 <a href="https://www.globenewswire.com/Tracker?data=qSG0EfLavLwmQkJzpmw5JU4WeBenUpgtOd0OZWQzc4FPXYN0QJ3qa21pEhC26DU0AjHmxSOogNqUV63nEwFwmwDLShdZRGO0LNPCbUxle5jpQOCaBzI2rHdaOkgoPwq6" rel="nofollow" target="_blank" title="shamsian@lythampartners.com">shamsian@lythampartners.com</a> <img alt="" src='https://ml.globenewswire.com/media/NDA0MTJjNGMtMTA3MS00MTJiLTk3MjEtYTg3NjI3MzA2MzM4LTEyNjM3OTUtMjAyNi0wNy0yOC1lbg==/tiny/NeurAxis-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn